← Patent Expiry Watch
October 8, 2026 · Patent expires January 15, 2030
Cabometyx (cabozantinib): The 2030-2031 Generic Opportunity Window
Exelixis's blockbuster kinase inhibitor, Cabometyx (cabozantinib), generated over $2.1 billion in US sales in 2025. Currently, the US market remains 100% brand-only. Core malate salt patents (US 11,091,439; 11,091,440; 11,098,015) expire on January 15, 2030. Secondary pharmaceutical composition patents extend Orange Book exclusivity to July 18, 2031. Following settlements with generic filers like Cipla and Teva, a clear generic entry window has opened between January 2030 and January 2031.
What we do
We track expirations like this continuously
This is one drug, picked for today's post. A Portfolio Retainer watches an entire portfolio or compound class on an ongoing basis and flags new matching filings as they publish.